Reflux, Intraocular Pressure Variation and Pain Following Intravitreal Ranibizumab Injections Using 30-Gauge or 32-Gauge Needles for Patients With Retinal Pathologies: A Randomized Clinical Trial

Saeed T. Alshahrani^{1, 2}, Uriel Rubin², Vasudha Gupta², Tom Gonder², Sanjay Sharma²

1. Ophthalmology Department, King Fahad Medical City, Riyadh, SAU 2. Ophthalmology, Queens University, Kingston, CAN

Corresponding author: Saeed T. Alshahrani, dr.eye2008@gmail.com

Abstract

Purpose: To compare reflux, intraocular pressure (IOP) variation and pain following intravitreal (IV) injections using 30-gauge and 32-gauge needles in patients with retinal pathologies in Saudi Arabia.

Methods: A double-blind randomized clinical trial was conducted in 2018. Participants were randomized to receive IV injections of Ranibizumab using 30-gauge (Gr₁) or 32-gauge (Gr₂) needles. The amount of reflux of injected material, IOP before (IOP₁) and five minutes after injection (IOP₂) were measured. The patient-perceived pain score was assessed using a visual analogue score (VAS). Outcome variables were compared.

Results: The study sample was comprised of 86 eyes (86 patients) in each group. Gender (P=0.76), laterality (P=0.55) and age (P=1.0) were not different between groups. The reflux in Gr₁ [34.9% (95% confidence interval [CI], 24.8; 45.0)] was significantly higher compared to Gr₂ [22.1% (95% CI, 13.3; 30.9)] (P=0.007). The median pain score was 1 in both Gr₁ [interquartile range (IQR) 1.0; 3.0] and Gr₂ (IQR 0.0; 2.0) (P=0.04). Among 56 eyes without reflux in Gr₁, the IOP₁ and IOP₂ were 13.6±2.7 mmHg and 16.4±5.0 mmHg, respectively. Among 67 eyes without reflux in Gr₂, the IOP₁ and IOP₂ were 13.6±2.9 mmHg and 17.0±5.2 mmHg, respectively. The change in percentage in IOP in Gr₁ and Gr₂ was not significantly different (Mann Whiney P=0.3).

Conclusions: IV injection given by 30-gauge needle compared to 32-gauge needle resulted in greater patient-perceived pain and more reflux of injected material from the injection site. An increase in IOP was not associated with the gauge of the needle used for IV injection.

Review began 02/17/2021

Review ended 03/31/2021

Published 04/06/2021

© Copyright 2021

Alshahrani et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Categories: Ophthalmology, Pain Management

Keywords: intravitreal injection, intra ocular pressure, retinal diseases, retina, vitreous

Introduction

Anti-vascular endothelial growth factor (VEGF) compounds are the initial treatment for diabetic macular edema (DME) with foveal involvement. These compounds can be used as isolated treatment or combined with photocoagulation [1,2]. Intravitreal (IV) injections of anti-VEGF compounds are performed on an outpatient basis for a number of other retinal pathologies [3,4]. IV injections of anti-VEGF compounds are known to cause short-term and sustained increases in intraocular pressure (IOP) [5,6]. Therefore, IOP monitoring is recommended soon after and at regular intervals following IV injections [6]. Patient compliance is vital for treatments that require repeat injections. Hence, patient-perceived discomfort and pain during intravitreal injections should be assessed and addressed as warranted [7-9]. For optimum availability of anti-VEGF medication in the vitreous cavity proximal to the site of pathology, different routes, different sites and different sized injections (gauge) have been investigated [10-12]. However, reflux occurs soon after intravitreal injection and it contains the injected material and vitreous. Fortunately, less than 1% of injected material is lost with reflux [13]. The reflux can vary by size of entry in the sclera and other layers of the globe depending on the needle gauge.

To the best of our knowledge, studies have compared outcomes of intravitreal injections using the different gauge of needles for 27 vs 30 and 30 vs 33 gauge needles but not 30 vs 32 gauge needles in Arab patients [11,12].

We present the results of a double-masked randomized clinical trial (RCT) comparing the reflux, short-term IOP and the patient-perceived pain among separate groups of patients managed with 30-gauge vs 32-gauge

How to cite this article

Alshahrani S T, Rubin U, Gupta V, et al. (April 06, 2021) Reflux, Intraocular Pressure Variation and Pain Following Intravitreal Ranibizumab Injections Using 30-Gauge or 32-Gauge Needles for Patients With Retinal Pathologies: A Randomized Clinical Trial. Cureus 13(4): e14320. DOI 10.7759/cureus.14320

needle for IV injection for different retinal pathologies.

Materials And Methods

Patients with macular edema due to diabetic retinopathy, exudative age-related macular edema or retinal vasculopathy visiting our institution for intravitreal anti-VEGF injection comprised the study population. The institution research and ethics committee approved this study and this study adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from each participant.

The field component of the study was carried out between January 2016 and December 2017. We included patients with retinal diseases mainly related to diabetes like DME and retinal vein occlusion needing IV injection. We excluded all not consenting to participate in the study.

We assumed that the conjunctival reflux would occur in 11.3% of eyes that received IV injection with a 30-gauge needle whereas the reflux rate was in 1% of eyes treated with a 32-gauge needle [13]. To achieve a 95% confidence interval (CI) and 80% power for this RCT with a 1:1 ratio for random allocation in each group, at least 86 eyes were required. The sample size was calculated with Open epi software [14].

Patients were randomly allocated to treatment with a 30-gauge needle (Gr1) or with a 32-gauge needle (Gr2). The Microsoft XL®'s random sample function was used to allocate patients in two arms of the study. The patient was not aware of the needle gauge used for intravitreal injection. The data analyzer was also masked about Gr1 and Gr2 identity.

Patients with macular edema agreeing to undergo management by IV injection of anti-VEGF compounds were included in the study. Patients were excluded if they declined to participate, had received intravitreal injection previously or experienced a painful ocular condition in addition to macular edema.

Demographic data were collected including patient age at presentation and gender. A retina specialist diagnosed the retinal pathology causing macular edema. The potential causes included age-related macular degeneration (AMD), DME or other retinal pathologies. The best-corrected visual acuity (BCVA) was recorded with ETDRS distance vision charts. Visual impairment was further graded as; normal functional vision (20/20 to 20/50), moderate visual impairment (<20/60 to 20/200), severe visual impairment (<20/200 to 20/400) and blind (<20/400) [15].

The procedure for IV injection used in the present study has been previously published [1,16]. Briefly, the eye was cleansed, and povidone-iodine and xylocaine gel were instilled, after 10 minutes an eye speculum was inserted, and povidone-iodine was instilled again. All intravitreal injections were performed by a retina specialist. The patient was asked to sit on an ophthalmic chair with chin up in a minor surgical procedure room. A mark at a distance of 3.5 cm from the limbus was placed in the inferotemporal quadrant to inject 0.05 ml containing 0.5 mg ranibizumab in the vitreous cavity.

Reflux was evaluated when we inject and we notice under the magnification of the operating microscope that some fluids get out from the injection site after we removed the needle which is considered as +ve reflux. The IOP was measured before and five minutes after IV injection using applanation XL (Medtronic, Minneapolis, MN). The difference in IOP before and five minutes after injection was used to calculate the percentage proportion of IOP change.

A visual analogue scale (VAS) was used to assess the patient-perceived severity of pain with a score from 1 to 10 [17].

Data were collected using a pretested data collection form, audited and then transferred to an Excel spreadsheet (Microsoft Corp., Redmond, WA). Data analysis was performed using Statistical Package for Social studies (SPSS 25; IBM Corp., Armonk, NY). For qualitative variable outcomes, univariate analysis with a parametric method was performed and frequencies and percentage proportions were calculated. For quantitative variables, the mean and standard deviation were reported for variables with a normal distribution. For a non-normal distribution, we estimated the median and interquartile range (IQR). To compare the pain score and IOP in two groups, we used a nonparametric method and estimated a two-sided P-value with the Mann-Whitney U test. The ordinal regression model was used to study the interaction of factors on the correlation of pain score to the gauge of the needle used for IV injection. A P-value less than 0.05 was considered statistically significant.

Results

We included 86 eyes of 86 patients in each group. The demographic and preoperative vision profile between groups was not significantly different (Table 1).

		Gr1 (30-gauge needle; n = 86)		Gr2 (32-gauge needle; n = 86)		Validation
		Number	Percentage	Number	Percentage	
Gender	Male	50	58.1	52	60.5	P = 0.76
	Female	36	41.9	34	39.5	
Laterality	Right eye	41	47.7	45	52.3	P = 0.55
	Left eye	45	52.3	41	47.7	
Vision impairment	20/20 to 20/60	5	8.9	9	13.4	P = 0.56
	<20/60 to 20/200	34	60.7	45	67.2	
	<20/200 to 20/400	7	12.5	2	3	
	<20/400	7	12.5	10	14.9	
	Missing	3	5.4	1	1.5	
Diagnosis	AMD	54	62.8	54	62.8	P = 1.0
	DME	32	37.2	32	37.2	
Age	Mean	77.8		77.8		P = 1.0
	SDV	10.7		10.7		

TABLE 1: Comparison of demographic and ocular profile before intravitreal injection using 30- and 32-gauge needle.

AMD: age-related macular degeneration, DME: diabetic macular edema, SDV: standard deviation.

Reflux was noted in 30 [34.9% (95% CI, 24.8:45.0)] eyes of Gr1 and 19 [22.1% (95% CI 13.3: 30.9)] eyes of Gr2. The reflux seems to be similar in Gr1 and Gr2 (P = 0.07).

Although the median of the pain score was 1 in both groups, the upper limit of IQR was more in Gr1 compared to that of Gr2. By using the nonparametric method of analysis, we noted that pain score was statistically significantly lower in Gr2 compared to Gr1 (Mann Whitney U test P = 0.04).

The IOP before and after IV injection is presented in Figure 1. The IOP increased five minutes after IV injection. However, there was no significant difference in IOP between groups. The median percentage difference in IOP before and after injection was 20% (IQR, 6: 38.5) for Gr1 and 22.5% (IQR, 5.8; 47.8) for Gr2. The percentage difference in IOP between groups was not significant (MW, P = 0.4). In Gr1, the IOP five minutes after IV injection was greater than 22 mmHg in 9 (10.5%) eyes. In Gr2 12 (14%) eyes had an IOP greater than 22 mmHg, five minutes after IV injection.

FIGURE 1: Intraocular pressure before and five minutes after intravitreal injection of anti-vascular growth factor (Ranibizumab) to treat macular edema.

The X-axis shows a 30-gauge needle (Gr1) used and a 32-gauge needle (Gr2) used for intravitreal injection and IOP before vs five minutes after intravitreal injection.

The Y-axis shows IOP in mmHg.

In the bar graph, the central symbol denotes the mean IOP value while two ends of the bar denote the lower and upper end of the 95% confidence interval.

Data on the change in IOP and pain score in eyes without reflux were analyzed. There were 56 eyes in Gr1 and 67 eyes in Gr2 that did not have reflux after IV injection. In these eyes, the median pain score in Gr1 was 1.0 (IQR 0.25: 3.0) and 1.0 (IQR 0.0: 2.0) in Gr2. The pain score was significantly lower in Gr2 compared to Gr1 (MW, $P = 0.04$). The median IOP before and after injection changed by 20% (IQR 7 32.5) in Gr1 and 25% (IQR 6; 47) in Gr2. The changes in IOP between groups were not statistically significant (MW, $P = 0.4$).

Using a logistic regression model, we noted that correlation of pain score to the gauge of the needle ($P = 0.05$) was not influenced by gender ($P = 0.3$), reflux ($P = 0.34$), age ($P = 0.64$) and eye involved ($P = 0.9$).

Discussion

The reflux in eyes that underwent IV injection with a 30-gauge needle and 32-gauge needle for the treatment of retinal pathologies causing macular edema was not significantly different. The pain perceived by patients was significantly higher with a 30-gauge needle compared to a 32-gauge needle. The IOP measured five minutes after intravitreal injection using a 30-gauge needle was one in ten eyes, while it was one in eight eyes that were injected by using a 32-gauge needle. Female gender, older age, presence of reflux and underlying retinal pathology causing macular edema did not significantly influence the association of perceived pain to the gauge of the needle used for IV injection.

This is perhaps the first study among Arab patients showing the outcomes of intravitreal injection using the different gauge of needles. As the use of preloaded injection cartridges for intravitreal drug delivery increases, our results support the use of smaller gauge needles and they perceive less pain as therefore more likely to be preferred by patients [18]. Additionally, the rise of IOP and reflux of injected material from smaller gauge needles were similar to 30-gauge needles. This matches with the results of Guller et al. who compared 27- vs 30-gauge needles for IV injection [11]. Van Asten et al. noted that less pain in the 33-gauge needle group than the 30-gauge needle group [12]. The use of larger gauge needles increases the opening in the sclera and uvea that can cause greater pain. The introduction of fluid in the vitreous cavity with greater velocity seems to cause more discomfort.

Reflux has been noted as less than 1% in in vitro studies [19]. However, in the in vivo studies by Lemos et al. and Lemos-Reis et al., the reflux rate was 11.3% and 21.3%, respectively [13,20]. The reflux was significantly greater when a 30-gauge needle was used compared to the 32-gauge needle [21]. In our study, it was as high as one in three eyes injected with 30-gauge needles and one in five eyes injected with 32-gauge needles. Thus, if we remove the eyes with reflux, the association of the gauge of the needle to perceived pain and IOP could change. Therefore, we had estimated outcomes in eyes without reflux also.

The patient-perceived pain score in our study was on the lower scale in both groups. Proper counseling prior to IV injection could have resulted in a lower pain score. Prior counseling and female gender have been reported to influence patient-perceived pain [12]. A study with a larger sample with prior counseling may yield a perceptible difference in pain scores between the two groups.

IOP rise following 0.5 mg in 0.05 ml Ranibizumab could be due to an increase in volume or physiological alterations within the globe. This IOP rises five minutes after was marginal and not significant. Lemos et al. have reported that subconjunctival reflux contributes to lowering IOP soon after intravitreal injection [13]. A greater IOP rise was noted after triamcinolone compared to ranibizumab injection [22]. Perhaps the property of the material injected rather than retained volume in the vitreous cavity could increase IOP after intravitreal injection. We found that fewer eyes experienced an increase in IOP in both groups compared to published studies [11,13,19].

There were some limitations to our study. The volume of reflux was not quantified. All patients were treated while seated. Hence, caution is urged with generalizing our findings to patients treated while supine.

Conclusions

With the rising population of diabetes and the trend of treating diabetic retinopathy with IV drug delivery, the selection of client-friendly but safe method is of interest to healthcare providers. The present study demonstrated that a 32-gauge needle compared to a 30-gauge needle was beneficial both for patients and service providers. The use of small-bore needles for intravitreal injection seems to reduce patient-perceived pain and maintain a lower level of side effects such as reflux and short-term rise of IOP.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. King Fahad Medical City, Saudi Arabia issued approval TRAQ #6016107. This was the thesis of Dr. Alshahrani for his fellowship and was approved by the institution where he was working at the time of research. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Preferred Practice Pattern® Guidelines. (2012). Accessed: April 06, 2021: <https://www.aao.org/about-preferred-practice-patterns>.
2. Wu CM, Wu AM, Young BK, Wu DJ, Margo CE, Greenberg PB: An appraisal of clinical practice guidelines for diabetic retinopathy. *Am J Med Qual.* 2016, 31:370-5. [10.1177/1062860615574863](https://doi.org/10.1177/1062860615574863)
3. Freund KB, Mrejen S, Gallego-Pinazo R: An update on the pharmacotherapy of neovascular age-related macular degeneration. *Expert Opin Pharmacother.* 2013, 14:1017-28. [10.1517/14656566.2013.787410](https://doi.org/10.1517/14656566.2013.787410)
4. Campochiaro PA, Clark WL, Boyer DS, et al.: Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. *Ophthalmology.* 2015, 122:538-44. [10.1016/j.ophtha.2014.08.031](https://doi.org/10.1016/j.ophtha.2014.08.031)
5. Seth RK, Salim S, Shields MB, Adelman RA: Assessment of optic nerve cup-to-disk ratio changes in patients receiving multiple intravitreal injections of antivascular endothelial growth factor agents. *Retina.* 2009, 29:956-9. [10.1097/IAE.0b013e3181a91dfd](https://doi.org/10.1097/IAE.0b013e3181a91dfd)
6. Bracha P, Moore NA, Ciulla TA, WuDunn D, Cantor LB: The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review. *Surv Ophthalmol.* 2018, 63:281-95. [10.1016/j.survophthal.2017.08.008](https://doi.org/10.1016/j.survophthal.2017.08.008)
7. Sanabria MR, Montero JA, Losada MV, et al.: Ocular pain after intravitreal injection. *Curr Eye Res.* 2013, 38:278-82. [10.3109/02713683.2012.758290](https://doi.org/10.3109/02713683.2012.758290)
8. Moisseiev E, Regenbogen M, Bartfeld Y, Barak A: Evaluation of pain in intravitreal bevacizumab injections. *Curr Eye Res.* 2012, 37:813-7. [10.3109/02713683.2012.681335](https://doi.org/10.3109/02713683.2012.681335)
9. Georgakopoulos CD, Tsapardoni F, Makri OE: Effect of Bromfenac on pain related to intravitreal injections - a randomized crossover study. *Retina.* 2017, 37:388-95. [10.1097/IAE.0000000000001137](https://doi.org/10.1097/IAE.0000000000001137)
10. Özkaya A, Alkin Z, Celik U, et al.: Comparing the effects of three different intravitreal injection techniques on vitreous reflux and intraocular pressure. *J Ocul Pharmacol Ther.* 2013, 29:325-9. [10.1089/jop.2012.0144](https://doi.org/10.1089/jop.2012.0144)
11. Güler M, Bilgin B, Çapkın M, Şimşek A, Bilak Ş: Assessment of patient pain experience during intravitreal 27-gauge bevacizumab and 30-gauge ranibizumab injection. *Korean J Ophthalmol.* 2015, 29:190-4. [10.3341/kjo.2015.29.3.190](https://doi.org/10.3341/kjo.2015.29.3.190)
12. van Asten F, van Middendorp H, Verkerk S, et al.: Are intravitreal injections with ultrathin 33-g needles less painful than the commonly used 30-G needles?. *Retina.* 2015, 35:1778-85. [10.1097/IAE.0000000000000550](https://doi.org/10.1097/IAE.0000000000000550)
13. Lemos V, Cabugueira A, Noronha M, Abegão Pinto L, Reina M, Branco J, Gomes T: Intraocular pressure in eyes receiving intravitreal antivascular endothelial growth factor injections. *Ophthalmologica.* 2015, 253:162-8. [10.1159/000369478](https://doi.org/10.1159/000369478)

14. Open source epidemiologic statistics for public health, Version . (2013). Accessed: October 3, 2018: <http://www.OpenEpi.com>.
15. International statistical classification of diseases and related health problems - 11th revision . (2016). Accessed: January 7, 2018: <https://icd.who.int/browse10/2016/en>.
16. Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, Schmidt-Erfurth U: 2018 update on intravitreal injections: EURETINA expert consensus recommendations. *Ophthalmologica*. 2018, 239:181-93. [10.1159/000486145](https://doi.org/10.1159/000486145)
17. Ong KS, Seymour RA: Pain measurement in humans . *Surgeon*. 2004, 2:15-27. [10.1016/s1479-666x\(04\)80133-1](https://doi.org/10.1016/s1479-666x(04)80133-1)
18. LUCENTIS - ranibizumab injection, solution in US library of medicine . (2021). Accessed: April 06, 2021: <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de4e66cc-ca05-4dc9-8262-e00e9b41c36d>.
19. Brodie FL, Ruggiero J, Ghodasra DH, Hui JZ, VanderBeek BL, Brucker AJ: Volume and composition of reflux after intravitreal injection. *Retina*. 2014, 34:1473-6. [10.1097/IAE.000000000000098](https://doi.org/10.1097/IAE.000000000000098)
20. Lemos-Reis R, Moreira-Gonçalves N, Melo AB, Carneiro AM, Falcão-Reis FM: Immediate effect of intravitreal injection of bevacizumab on intraocular pressure. *Clin Ophthalmol*. 2014, 8:1383-8. [10.2147/OPTH.S64721](https://doi.org/10.2147/OPTH.S64721)
21. Pang CE, Mrejen S, Hoang QV, Sorenson JA, Freund KB: Association between needle size, postinjection reflux, and intraocular pressure spikes after intravitreal injections. *Retina*. 2015, 35:1401-6. [10.1097/IAE.0000000000000476](https://doi.org/10.1097/IAE.0000000000000476)
22. Arian G, Osman Saatci A, Hakan Oner F: Immediate intraocular pressure rise after intravitreal injection of ranibizumab and two doses of triamcinolone acetonide. *Int J Ophthalmol*. 2011, 4:402-5. [10.3980/j.issn.2222-3959.2011.04.16](https://doi.org/10.3980/j.issn.2222-3959.2011.04.16)